Perrigo Earnings: Divestitures Remove Some Uncertainty, but Path Back to Normal Remains Challenged
Perrigo reported a 5% (or 2% organic) and 9% decline in revenue and adjusted EPS, respectively, during the third fiscal quarter. Shares are up 3%.
Perrigo Co PLC PRGO
Bulls Say, Bears Say
Bulls
Perrigo is now more tapped into the higher-margin branded consumer health market, which should act as a tailwind to the top and bottom lines.
Bears
By expanding its business to focus more on branded products, Perrigo now faces stiffer competition from larger consumer healthcare product manufacturers.
News
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Perrigo Announces Quarterly Dividend
Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
Perrigo to Attend the Barclays Global Consumer Conference
Articles & Videos
Trading Information
- Previous Close Price
- $16.95
- Day Range
- $16.21–16.92
- 52-Week Range
- $9.23–17.02
- Bid/Ask
- $16.29 / $17.00
- Shares Outstanding
- 138.80M
- Market Cap
- $2.34B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 6.73
- Price/Sales
- 0.57
- Dividend Yield (Trailing)
- 6.89%
- Dividend Yield (Forward)
- 6.89%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 6.89%
Company Profile
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm’s product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women’s health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 8,100
- Website
- https://www.perrigo.com
Competitors
Valuation
Metric | PRGO | PG | HLN |
|---|---|---|---|
Price/Earnings (Normalized) | 6.73 | 24.44 | 18.87 |
Price/Book Value | 0.96 | 7.12 | 1.84 |
Price/Sales | 0.57 | 4.63 | 2.71 |
Price/Cash Flow | 11.54 | 21.02 | 13.99 |
Price/Earnings
PRGO
PG
HLN
Financial Strength
Metric | PRGO | PG | HLN |
|---|---|---|---|
Quick Ratio | 1.10 | 0.49 | 0.51 |
Current Ratio | 2.35 | 0.72 | 0.69 |
Interest Coverage | −9.30 | 23.11 | 7.45 |
Quick Ratio
PRGO
PG
HLN
Profitability
Metric | PRGO | PG | HLN |
|---|---|---|---|
Return on Assets (Normalized) | −2.77% | 12.95% | 5.49% |
Return on Equity (Normalized) | −7.79% | 30.92% | 10.94% |
Return on Invested Capital (Normalized) | −1.41% | 18.72% | 8.05% |
Return on Assets
PRGO
PG
HLN
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|wCLMD&@ | LOCK|s$@t | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|%M@&>&L | LOCK|?Bj? | $50B | |||
| Haleon PLC ADR HLN | LOCK|b^!@YH> | LOCK|%?w | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|T$V<SxY& | LOCK|vQ | $34B | |||
| Viatris Inc VTRS | LOCK|n%bZhZ | LOCK|!RB | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|T%% | LOCK|@# | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|?D?J&@$ | LOCK|S?S | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|L@>CSDf | LOCK|%&z | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|r!Jgxt | LOCK|$?<& | $2B |
United States